Fluticasone + Salmeterol is a combination inhaler medication used to treat asthma and chronic obstructive pulmonary disease. It delivers a corticosteroid called fluticasone to reduce airway inflammation. It also contains salmeterol, a long-acting bronchodilator that relaxes the muscles around the airways. Together they improve lung function and decrease the frequency of respiratory symptoms. Fluticasone works by binding to glucocorticoid receptors in inflammatory cells, inhibiting the production of substances that cause swelling and mucus secretion. Salmeterol stimulates beta-2 adrenergic receptors on airway smooth muscle, leading to muscle relaxation and easier breathing. By decreasing inflammation and opening airways, the medication helps prevent asthma attacks and improves daily symptom control. This dual action addresses both the chronic inflammation and the bronchoconstriction that characterize obstructive lung diseases.

Fluticasone + Salmeterol is a combination inhaler that contains a synthetic glucocorticoid and a long-acting beta-agonist. Fluticasone functions as an anti-inflammatory agent that binds to glucocorticoid receptors to suppress the release of cytokines and immune cell activation. Salmeterol acts as a bronchodilator that stimulates beta-2 adrenergic receptors on airway smooth muscle leading to muscle relaxation. The synergistic effect of these two components improves long-term control of asthma and chronic obstructive pulmonary disease symptoms. By reducing airway inflammation and maintaining bronchiolar patency the medication enhances airflow and diminishes exacerbation frequency. Pharmacologically the drug is delivered via aerosol particles that deposit in the lungs ensuring high local concentration with minimal systemic exposure. The mechanism of action involves activation of intracellular signaling pathways that ultimately cause transcription of anti-inflammatory genes and inhibition of bronchoconstrictive mediators. This dual-mode of action provides sustained improvement in respiratory function for patients with chronic respiratory conditions.

Fluticasone with salmeterol may increase the risk of oral fungal infections such as thrush. It can cause hoarseness or irritation of the throat. Headache and muscle aches are among the commonly reported sensations. In rare cases the combination may contribute to pneumonia. Some individuals experience elevated blood pressure or irregular heart rhythms. Tremors or feelings of nervousness have been observed occasionally. Long-term use may affect bone mineral density in susceptible people.

The combination inhaler contains fluticasone and salmeterol for asthma maintenance. Local side effects such as throat irritation and hoarseness are commonly reported. Oral thrush can develop due to corticosteroid deposition in the mouth. Systemic effects like adrenal suppression are rare but documented with prolonged use. Cardiovascular responses including palpitations or increased heart rate may occur infrequently. Mild wheezing or symptom worsening can arise if the device is misused.